Northland Capital Markets Remains bullish on Nxstage Medical (NXTM) Following Field Checks

September 14, 2016 10:43 AM EDT
Get Alerts NXTM Hot Sheet
Price: $25.37 +2.34%

Rating Summary:
    9 Buy, 3 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 15 | New: 18
Trade NXTM Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Northland Capital Markets reiterated an Outperform rating and $25.00 price target on NxStage Medical (NASDAQ: NXTM) following recent checks.

Analyst Suraj Kalia commented, "Our recent due diligence calls with experts & site visit to NXTM lead us to believe that NxStage' 5-yr forecast will be critically dependent on the timing of the rollouts, reliability of the products & how execution risk is managed. We believe that NxStage "probably" can deliver on its 5-yr goals. However, more importantly, the on-demand PD cycler could cause seismic shifts in the space, and force the big boys to respond. In our view, that is the significant call option in this story to play."

For an analyst ratings summary and ratings history on NxStage Medical click here. For more ratings news on NxStage Medical click here.

Shares of NxStage Medical closed at $23.05 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Add Your Comment